Status:
TERMINATED
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Japan. This is a clinical trial to study the efficacy and safety of thrice daily Insulin Aspart compared to Glibenclamide in type 2 diabetic patients.
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s) other than SU agents for at least 12 weeks
- No previous treatment with insulin and/or SU agents
- HbA1c between 7.5% and 10.0%
- Body Mass Index (BMI) below 30.0 kg/m2
Exclusion
- Proliferative retinopathy or maculopathy requiring acute treatment
- Impaired hepatic function
- Impaired renal function
- Cardiac diseases
- Uncontrolled hypertension
- Known hypoglycaemia unawareness or recurrent major hypoglycaemia
- Current treatment with systemic corticosteroids
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00267683
Start Date
December 1 2005
End Date
April 1 2006
Last Update
November 2 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.